Search company, investor...

Founded Year



Series A | Dead

Total Raised


Last Raised


About Marillion Pharmaceuticals

Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..

Headquarters Location

102 Pickering Way Suite 200

Exton, Pennsylvania, 19341,

United States




Marillion Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Marillion Pharmaceuticals founded?

    Marillion Pharmaceuticals was founded in 2005.

  • Where is Marillion Pharmaceuticals's headquarters?

    Marillion Pharmaceuticals's headquarters is located at 102 Pickering Way, Exton.

  • What is Marillion Pharmaceuticals's latest funding round?

    Marillion Pharmaceuticals's latest funding round is Series A.

  • How much did Marillion Pharmaceuticals raise?

    Marillion Pharmaceuticals raised a total of $2M.

  • Who are the investors of Marillion Pharmaceuticals?

    Investors of Marillion Pharmaceuticals include APIDC Venture Capital and BioAdvance.

  • Who are Marillion Pharmaceuticals's competitors?

    Competitors of Marillion Pharmaceuticals include Reata Pharmaceuticals, Diasome, Concert Pharmaceuticals, Adastra Pharmaceuticals, Vasopharm and 7 more.


Compare Marillion Pharmaceuticals to Competitors


Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.

Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

The DNA Repair Company

The DNA Repair Company was founded to bring recent scientific discoveries from the Dana Farber Cancer Institute and the Massachusetts Institute of Technology to the clinic to benefit cancer patients. Breakthroughs in understanding DNA repair mechanisms have led to new personalized approaches to cancer treatment, beginning with diagnostic tools that improve the efficacy of currently available cancer therapies, as well as drugs under development. DNAR exists to make these tools available to physicians with the goal of improving clinical outcomes.

PNP Therapeutics

PNP Therapeutics is a clinical-stage, biopharmaceutical company focused on the development of a platform technology and proprietary products in the healthcare and pharmaceutical industry. The company's main offerings include the development of treatments for cancer. It is based in Birmingham, Alabama.


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and well-being in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.


MuriGen is building a portfolio of drugs for unmet medical needs across a number of therapeutic areas including cancer, arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.